ReNeuron Group plc Directors Share Purchases (2127C)
September 27 2018 - 10:02AM
UK Regulatory
TIDMRENE
RNS Number : 2127C
ReNeuron Group plc
27 September 2018
27 September 2018 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
Directors Share Purchases
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, was informed on 27
September 2018 that, on the same day, the following purchases of
the Company's ordinary shares of 1p each ("Ordinary Shares") were
made by directors of the Company:
Name Title Number Total beneficial Percentage
of Ordinary interest in of Company's
Shares the Company's Total Voting
purchased Ordinary Shares Rights
Chief Executive
Olav Hellebø Officer 14,936 21,630 0.068
----------------- ------------- ----------------- --------------
Chief Financial
Michael Hunt Officer 7,462 27,546 0.087
----------------- ------------- ----------------- --------------
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to purchase of Ordinary Shares)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Olav Hellebo
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI N/A
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of the Ordinary Shares 0.01p
financial instrument,
type of instrument RENE - GB00B0DZML60
Identification code
--------------------------- -----------------------------------
b) Nature of the transaction Purchase of ordinary shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
66.9p 14,936
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 27 September 2018
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Michael Hunt
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI N/A
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of the Ordinary Shares 0.01p
financial instrument,
type of instrument RENE - GB00B0DZML60
Identification code
--------------------------- -----------------------------------
b) Nature of the transaction Purchase of ordinary shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
67p 7,462
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 27 September 2018
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFEVATIDFIT
(END) Dow Jones Newswires
September 27, 2018 10:02 ET (14:02 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024